Long-term  ||| S:0 E:10 ||| JJ
use  ||| S:10 E:14 ||| NN
of  ||| S:14 E:17 ||| IN
mobile  ||| S:17 E:24 ||| JJ
phone  ||| S:24 E:30 ||| NN
and  ||| S:30 E:34 ||| CC
its  ||| S:34 E:38 ||| PRP$
association  ||| S:38 E:50 ||| NN
with  ||| S:50 E:55 ||| IN
glioma ||| S:55 E:61 ||| NNS
:  ||| S:61 E:63 ||| :
a  ||| S:63 E:65 ||| DT
systematic  ||| S:65 E:76 ||| JJ
review  ||| S:76 E:83 ||| NN
and  ||| S:83 E:87 ||| CC
meta-analysis  ||| S:87 E:101 ||| JJ
The  ||| S:101 E:105 ||| DT
hypothesis  ||| S:105 E:116 ||| NN
that  ||| S:116 E:121 ||| IN
cell  ||| S:121 E:126 ||| NN
phone  ||| S:126 E:132 ||| NN
induces  ||| S:132 E:140 ||| VBZ
brain  ||| S:140 E:146 ||| NN
tumor  ||| S:146 E:152 ||| NN
has  ||| S:152 E:156 ||| VBZ
become  ||| S:156 E:163 ||| VBN
a  ||| S:163 E:165 ||| DT
target  ||| S:165 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
much  ||| S:175 E:180 ||| JJ
controversy  ||| S:180 E:192 ||| NN
for  ||| S:192 E:196 ||| IN
several  ||| S:196 E:204 ||| JJ
decades  ||| S:204 E:212 ||| NNS
and  ||| S:212 E:216 ||| CC
is  ||| S:216 E:219 ||| VBZ
still  ||| S:219 E:225 ||| RB
a  ||| S:225 E:227 ||| DT
matter  ||| S:227 E:234 ||| NN
of  ||| S:234 E:237 ||| IN
debate  ||| S:237 E:244 ||| NN
even  ||| S:244 E:249 ||| RB
now ||| S:249 E:252 ||| RB
.  ||| S:252 E:254 ||| .
We  ||| S:254 E:257 ||| PRP
aim  ||| S:257 E:261 ||| VBP
to  ||| S:261 E:264 ||| TO
make  ||| S:264 E:269 ||| VB
a  ||| S:269 E:271 ||| DT
systematic  ||| S:271 E:282 ||| JJ
review  ||| S:282 E:289 ||| NN
and  ||| S:289 E:293 ||| CC
meta-analysis  ||| S:293 E:307 ||| JJ
based  ||| S:307 E:313 ||| VBN
on  ||| S:313 E:316 ||| IN
published  ||| S:316 E:326 ||| JJ
studies  ||| S:326 E:334 ||| NNS
on  ||| S:334 E:337 ||| IN
glioma  ||| S:337 E:344 ||| VBG
to  ||| S:344 E:347 ||| TO
identify  ||| S:347 E:356 ||| VB
current  ||| S:356 E:364 ||| JJ
evidences  ||| S:364 E:374 ||| NN
for  ||| S:374 E:378 ||| IN
evaluating  ||| S:378 E:389 ||| VBG
mobile  ||| S:389 E:396 ||| JJ
phones  ||| S:396 E:403 ||| NNS
and  ||| S:403 E:407 ||| CC
glioma  ||| S:407 E:414 ||| JJ
risk ||| S:414 E:418 ||| NN
,  ||| S:418 E:420 ||| ,
especially  ||| S:420 E:431 ||| RB
on  ||| S:431 E:434 ||| IN
long-term  ||| S:434 E:444 ||| JJ
use  ||| S:444 E:448 ||| NN
of  ||| S:448 E:451 ||| IN
mobile  ||| S:451 E:458 ||| JJ
phones ||| S:458 E:464 ||| NNS
.  ||| S:464 E:466 ||| .
The  ||| S:466 E:470 ||| DT
study  ||| S:470 E:476 ||| NN
was  ||| S:476 E:480 ||| VBD
conducted  ||| S:480 E:490 ||| VBN
according  ||| S:490 E:500 ||| VBG
to  ||| S:500 E:503 ||| TO
the  ||| S:503 E:507 ||| DT
Cochrane  ||| S:507 E:516 ||| JJ
systematic  ||| S:516 E:527 ||| JJ
review  ||| S:527 E:534 ||| NN
methods  ||| S:534 E:542 ||| NNS
and  ||| S:542 E:546 ||| CC
reported  ||| S:546 E:555 ||| VBD
according  ||| S:555 E:565 ||| VBG
to  ||| S:565 E:568 ||| TO
the  ||| S:568 E:572 ||| DT
PRISMA  ||| S:572 E:579 ||| NNP
( ||| S:579 E:580 ||| -LRB-
Preferred  ||| S:580 E:590 ||| NNP
Reporting  ||| S:590 E:600 ||| NNP
Items  ||| S:600 E:606 ||| NNS
for  ||| S:606 E:610 ||| IN
Systematic  ||| S:610 E:621 ||| NNP
reviews  ||| S:621 E:629 ||| NNS
and  ||| S:629 E:633 ||| CC
Meta-Analyses ||| S:633 E:646 ||| NNP
)  ||| S:646 E:648 ||| -RRB-
statement  ||| S:648 E:658 ||| NN
according  ||| S:658 E:668 ||| VBG
to  ||| S:668 E:671 ||| TO
a  ||| S:671 E:673 ||| DT
prospective  ||| S:673 E:685 ||| JJ
research  ||| S:685 E:694 ||| NN
protocol  ||| S:694 E:703 ||| NN
accessed  ||| S:703 E:712 ||| NN
via  ||| S:712 E:716 ||| IN
http ||| S:716 E:720 ||| NNS
: ||| S:720 E:721 ||| :
-www.crd.york.ac.uk ||| S:721 E:740 ||| CD
/ ||| S:740 E:741 ||| CD
prospero ||| S:741 E:749 ||| NNS
.  ||| S:749 E:751 ||| .
The  ||| S:751 E:755 ||| DT
software  ||| S:755 E:764 ||| NN
RevMan  ||| S:764 E:771 ||| JJ
5  ||| S:771 E:773 ||| CD
was  ||| S:773 E:777 ||| VBD
used  ||| S:777 E:782 ||| VBN
for  ||| S:782 E:786 ||| IN
statistic  ||| S:786 E:796 ||| JJ
analysis ||| S:796 E:804 ||| NN
.  ||| S:804 E:806 ||| .
Latency  ||| S:806 E:814 ||| NNP
and  ||| S:814 E:818 ||| CC
lateralization  ||| S:818 E:833 ||| NNS
were  ||| S:833 E:838 ||| VBD
used  ||| S:838 E:843 ||| VBN
for  ||| S:843 E:847 ||| IN
the  ||| S:847 E:851 ||| DT
examining  ||| S:851 E:861 ||| VBG
the  ||| S:861 E:865 ||| DT
dose-response  ||| S:865 E:879 ||| JJ
relationship ||| S:879 E:891 ||| NN
.  ||| S:891 E:893 ||| .
Overall  ||| S:893 E:901 ||| JJ
evidence  ||| S:901 E:910 ||| NN
suggested  ||| S:910 E:920 ||| VBD
the  ||| S:920 E:924 ||| DT
increased  ||| S:924 E:934 ||| JJ
risk  ||| S:934 E:939 ||| NN
of  ||| S:939 E:942 ||| IN
glioma  ||| S:942 E:949 ||| NN
among  ||| S:949 E:955 ||| IN
long-term  ||| S:955 E:965 ||| JJ
ipsilateral  ||| S:965 E:977 ||| JJ
users  ||| S:977 E:983 ||| NNS
of  ||| S:983 E:986 ||| IN
mobile  ||| S:986 E:993 ||| JJ
phone  ||| S:993 E:999 ||| NN
with  ||| S:999 E:1004 ||| IN
an  ||| S:1004 E:1007 ||| DT
odds  ||| S:1007 E:1012 ||| JJ
ratio  ||| S:1012 E:1018 ||| NN
( ||| S:1018 E:1019 ||| -LRB-
OR ||| S:1019 E:1021 ||| NNP
)  ||| S:1021 E:1023 ||| -RRB-
of  ||| S:1023 E:1026 ||| IN
1.46 ||| S:1026 E:1030 ||| CD
[ ||| S:1030 E:1031 ||| -LRB-
1.12 ||| S:1031 E:1035 ||| CD
,  ||| S:1035 E:1037 ||| ,
1.92 ||| S:1037 E:1041 ||| CD
]  ||| S:1041 E:1043 ||| -RRB-
based  ||| S:1043 E:1049 ||| VBN
on  ||| S:1049 E:1052 ||| IN
meta-analysis ||| S:1052 E:1065 ||| JJ
.  ||| S:1065 E:1067 ||| .
Especially ||| S:1067 E:1077 ||| RB
,  ||| S:1077 E:1079 ||| ,
for  ||| S:1079 E:1083 ||| IN
low-grade  ||| S:1083 E:1093 ||| JJ
glioma ||| S:1093 E:1099 ||| NN
,  ||| S:1099 E:1101 ||| ,
long-term  ||| S:1101 E:1111 ||| JJ
use  ||| S:1111 E:1115 ||| NN
yielded  ||| S:1115 E:1123 ||| VBD
an  ||| S:1123 E:1126 ||| DT
OR  ||| S:1126 E:1129 ||| NNP
value  ||| S:1129 E:1135 ||| NN
of  ||| S:1135 E:1138 ||| IN
2.27  ||| S:1138 E:1143 ||| CD
[ ||| S:1143 E:1144 ||| -LRB-
1.81 ||| S:1144 E:1148 ||| CD
,  ||| S:1148 E:1150 ||| ,
2.85 ||| S:1150 E:1154 ||| CD
] ||| S:1154 E:1155 ||| -RRB-
.  ||| S:1155 E:1157 ||| .
The  ||| S:1157 E:1161 ||| DT
evidence  ||| S:1161 E:1170 ||| NN
is  ||| S:1170 E:1173 ||| VBZ
currently  ||| S:1173 E:1183 ||| RB
insufficient  ||| S:1183 E:1196 ||| JJ
on  ||| S:1196 E:1199 ||| IN
this  ||| S:1199 E:1204 ||| DT
issue ||| S:1204 E:1209 ||| NN
,  ||| S:1209 E:1211 ||| ,
especially  ||| S:1211 E:1222 ||| RB
on  ||| S:1222 E:1225 ||| IN
long-term  ||| S:1225 E:1235 ||| JJ
use  ||| S:1235 E:1239 ||| NN
of  ||| S:1239 E:1242 ||| IN
mobile  ||| S:1242 E:1249 ||| JJ
phone ||| S:1249 E:1254 ||| NN
.  ||| S:1254 E:1256 ||| .
Neither  ||| S:1256 E:1264 ||| CC
a  ||| S:1264 E:1266 ||| DT
definite  ||| S:1266 E:1275 ||| JJ
answer  ||| S:1275 E:1282 ||| NN
nor  ||| S:1282 E:1286 ||| CC
a  ||| S:1286 E:1288 ||| DT
clear  ||| S:1288 E:1294 ||| JJ
explanation  ||| S:1294 E:1306 ||| NN
may  ||| S:1306 E:1310 ||| MD
be  ||| S:1310 E:1313 ||| VB
offered  ||| S:1313 E:1321 ||| VBN
for  ||| S:1321 E:1325 ||| IN
the  ||| S:1325 E:1329 ||| DT
relationship ||| S:1329 E:1341 ||| NN
.  ||| S:1341 E:1343 ||| .
And  ||| S:1343 E:1347 ||| CC
larger  ||| S:1347 E:1354 ||| JJR
prospective  ||| S:1354 E:1366 ||| JJ
trials  ||| S:1366 E:1373 ||| NNS
are  ||| S:1373 E:1377 ||| VBP
warranted ||| S:1377 E:1386 ||| VBN
.  ||| S:1386 E:1388 ||| .
